Nothing said here yet.
to join the conversation.
| Malik Fady IbrahamEVP Research & Development | Sell | 3,500 | $224.0K | Tue, Oct 20 |
| Blum Robert IPresident & CEO | Sell | 7,500 | $471.6K | Mon, Oct 12 |
| Malik Fady IbrahamEVP Research & Development | Sell | 3,500 | $214.8K | Tue, Oct 6 |
| Blum Robert IPresident & CEO | Sell | 7,500 | $490.9K | Mon, Sep 28 |
| Malik Fady IbrahamEVP Research & Development | Sell | 3,500 | $239.0K | Tue, Sep 22 |
| Blum Robert IPresident & CEO | Sell | 97,926 | $6.8M | Tue, Sep 15 |
| Landry Robert EDirector | Sell | 1,000 | $72.1K | Tue, Sep 15 |
| Blum Robert IPresident & CEO | Sell | 7,500 | $550.8K | Mon, Sep 14 |
| Landry Robert EDirector | Sell | 1,000 | $74.7K | Fri, Sep 11 |
| Malik Fady IbrahamEVP Research & Development | Sell | 3,500 | $264.1K | Tue, Sep 8 |
| PARSHALL B LYNNEDirector | Sell | 5,000 | $357.4K | Tue, Sep 1 |
| Callos AndrewEVP, Chief Commercial Officer | Sell | 10,000 | $702.4K | Mon, Aug 31 |
| Gilbert Cisneros | Buy | $8.0K | Tue, Sep 29 | Fri, Oct 9 |
| Gilbert Cisneros | Buy | $8.0K | Tue, Jun 30 | Thu, Jul 2 |
Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 2026 at 4:00 PM Eastern Time.
BridgeBio Pharma (BBIO), Madrigal Pharmaceuticals (MDGL) and Cytokinetics (CYTK) traded meaningfully
Cytokinetics' Myqorzo gains commercial traction with growing prescriptions, international launches and promising clinical data that could expand its market opportunity.
Cytokinetics recently presented additional Phase 3 ACACIA-HCM data at the 2026 HFSA meeting, showing aficamten improved global exercise performance in adults with non-obstructive hypertrophic cardiomyopathy using the new BEAP-RS composite score.
Cytokinetics (CYTK) is back in focus after sharing new Phase 3 ACACIA-HCM data for aficamten at the Heart Failure Society of America meeting in Phoenix, highlighting exercise performance outcomes in non-obstructive hypertrophic cardiomyopathy.
Cytokinetics has delivered a sizeable 81.2% share price gain over the past three years, helped by fresh momentum around its heart drugs.
Cytokinetics (NasdaqGS: CYTK) reported new Phase 3 ACACIA-HCM data showing aficamten improved exercise performance in non-obstructive HCM patients.
SOUTH SAN FRANCISCO, Calif., Oct.